<DOC>
	<DOCNO>NCT01481597</DOCNO>
	<brief_summary>Deuteporfin , novel photodynamic drug develop China , display good photodynamic antitumor activity . The purpose present study investigate safety pharmacokinetics intravenous deuteporfin healthy Chinese volunteer follow single-dose administration .</brief_summary>
	<brief_title>Deuteporfin Tolerance Pharmacokinetics Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Chinese healthy male and/or female subject 18 45 year old Body mass index ( BMI ) within range 19 24 kg/m2 weigh least 45 kg female subject 50 kg male subject In good health confirm past medical history , physical examination , electrocardiogram , laboratory test urinalysis screen baseline evaluation Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure Significant illness major surgery within four week prior dose Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy photoallergy ) Use drug might interfere drug absorption , distribution , metabolism , excretion cause photoallergy within 30 day prior dose , drug within 14 day prior dose Participation clinical investigation within 30 day prior dose Smokers , alcoholic , drug abuser Immunodeficiency disease , include positive HIV test result , Positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result pregnancy lactation female subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>deuteporfin</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>